This postmarketing study will examine the use of etoricoxib (Arcoxia®) in routine clinical practice in France as well as the use of celecoxib (Celebrex®).
Read more: http://www.clinicaltrials.gov/ct2/show/NCT01572675?cond=%22Arthritis%22&lup_s=01/29/2014&lup_d=30
